| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITOS | Common Stock | Sale | -$410K | -14.9K | -0.29% | $27.53 | 5.15M | Oct 15, 2021 | See Footnote | F1, F2, F3, F4, F5 |
| transaction | ITOS | Common Stock | Sale | -$95.6K | -3.41K | -0.07% | $28.01 | 5.15M | Oct 15, 2021 | See Footnote | F1, F6, F7, F8 |
| transaction | ITOS | Common Stock | Sale | -$280K | -10.3K | -0.2% | $27.14 | 5.14M | Oct 18, 2021 | See Footnote | F1, F9, F10, F11 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. |
| F2 | The shares were sold as follows: 5,298 by MPM BioVentures 2014, L.P. ("BV 2014"), 182 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 3,347 by MPM BioVentures 2018, L.P. ("BV 2018"), 66 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 5,989 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. |
| F3 | BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The shares are held as follows: 1,776,194 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 61,134 by AM BV2014, 1,121,805 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 22,138 by AM BV2018 and 2,007,750 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
| F6 | The shares were sold as follows: 1,215 by BV 2014, 42 by AM BV2014, 767 by BV 2018, 15 by AM BV2018 and 1,374 by UBS Oncology. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The shares are held as follows: 1,774,979 by BV 2014, 107,713 by BV 2014(B), 61,092 by AM BV2014, 1,121,038 by BV 2018, 54,213 by BV 2018(B), 22,123 by AM BV2018 and 2,006,376 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
| F9 | The shares were sold as follows: 3,676 by BV 2014, 125 by AM BV2014, 2,321 by BV 2018, 45 by AM BV2018 and 4,153 by UBS Oncology. |
| F10 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 to $27.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F11 | The shares are held as follows: 1,771,303 by BV 2014, 107,713 by BV 2014(B), 60,967 by AM BV2014, 1,118,717 by BV 2018, 54,213 by BV 2018(B), 22,078 by AM BV2018 and 2,002,223 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |